Condition
HTLV-I Infections
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 5 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 4 (1)
Trial Status
Completed5
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03829709Not ApplicableCompletedPrimary
Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1
NCT02655471Early Phase 1CompletedPrimary
Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection
NCT03226119Phase 4CompletedPrimary
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
NCT01754311CompletedPrimary
Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1
NCT03146013CompletedPrimary
Dual Algorithm Post Market Clinical Study
NCT01467024UnknownPrimary
Evaluation of the MP Diagnostics HTLV Blot 2.4
Showing all 6 trials